<DOC>
	<DOCNO>NCT01890109</DOCNO>
	<brief_summary>This randomize , stratify , double-blind , placebo-controlled , parallel-group study female subject HFs associate menopause . This study evaluate efficacy AMG 334 measure reduction baseline frequency severity daily HFs week 2 , 4 , 8 , 12 , 16 single dose AMG 334 .</brief_summary>
	<brief_title>Randomized , Parallel-group , Double-blind , Placebo-controlled , Study AMG 334 Women With Hot Flashes</brief_title>
	<detailed_description>This randomize , stratify , double-blind , placebo-controlled , parallel-group study female subject HFs associate menopause . This study evaluate efficacy AMG 334 measure reduction baseline frequency severity daily HFs week 2 , 4 , 8 , 12 , 16 single dose AMG 334 . Study Phase : 1b Primary Objective : To evaluate frequency moderate severe daily HFs week 4 single dose AMG 334 female subject HFs associate menopause . Secondary Objectives : To evaluate change severity daily HFs week 4 single dose AMG 334 female subject moderate severe HFs associate menopause . To evaluate safety , tolerability , immunogenicity AMG 334 female subject HFs associate menopause To characterize pharmacokinetic ( PK ) profile AMG 334 single subcutaneous ( SC ) dose female subject HFs associate menopause Hypotheses : This study test hypothesis vasodilation associate capsaicin-induced dermal blood flow ( DBF ) provide good model vasodilation associate HFs ; therefore AMG 334 dos cause DBF inhibition safe well tolerate , effective reduction frequency and/or severity HFs .</detailed_description>
	<mesh_term>Hot Flashes</mesh_term>
	<criteria>female subject hot flash associate menopause 45 65 year age , inclusive , history evidence clinically relevant medical disorder determine investigator consultation Amgen physician . History evidence clinically significant disorder ( include psychiatric ) , condition disease , opinion Investigator Amgen physician would pose risk subject safety interfere study evaluation , procedure , completion .</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Vasomotor symptom ; Hot Flashes</keyword>
</DOC>